Navigation Links
Global Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
Date:12/27/2013

DUBLIN, December 27, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/3zf33c/erectile) have announced the addition of the "Global Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Erectile dysfunction (ED) is the inability to achieve or maintain satisfactory erection of penis during sexual intercourse. It is usually an age related condition but can also be triggered by psychological factors. It may occur due to various reasons such as smoking, sedentary lifestyle and administration of certain drugs such as antidepressants, psychotropic drugs, antihypertensive and recreational drugs.

Presently, oral phosphodiesterase type 5 inhibitors (PDE 5) commonly form the first line of treatment prescribed by doctors for ED. These include drugs namely, Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil) and Zydena (udenafil). The demand for erectile dysfunction drugs is high and is continuously rising as it caters to the needs of the growing elderly population and the high incidence rates of chronic disorders comprising hypertension, renal diseases and diabetes, neurological disorders and hormonal insufficiencies.

This report studies the global erectile dysfunction drugs market with a major focus on the branded drugs which include Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil) and others such as MUSE (Medicated Urethral System for Erections), Mvix and Helleva.

Pipeline analysis for drugs namely, Vitaros (alprostadil), Uprima (apomorphine) and others have also been included in the report. Market size and forecasts for the period 2010 - 2019 have been provided for each of the drugs, in terms of USD million, considering historical data for 2010 and 2011, and base year as 2012. The % compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 - 2019 has also been provided along with market size estimations.

Key Topics Covered:

1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations

2 Executive Summary

3 Market Overview
3.1 Introduction to Erectile Dysfunction
3.2 Current Market Trends and Future Outlook
3.3 Types of Treatments for ED
3.4 Market Drivers
3.5 Market Restraints
3.6 Market Opportunities
3.7 Porter's Five Forces Analysis: Global Erectile Dysfunction Drugs Market
3.8 Market Attractiveness Analysis: Global Erectile Dysfunction Drugs Market, By Geography (2015)

4 Global Erectile Dysfunction Drugs Market Revenue, By Brand, 2011-2019 (USD Million)
4.1 Market Overview
4.2 Viagra (Sildenafil Citrate)
4.3 Cialis (Tadalafil)
4.4 Levitra/Staxyn (Vardenafil)
4.5 Stendra/Spedra (Avanafil)
4.6 Zydena (Udenafil)
4.7 MUSE (Medicated Urethral System for Erection)
4.8 Mvix (Mirodenafil)
4.9 Helleva (Lodenafil Carbonate)

5 Global Erectile Dysfunction Drugs Market, Pipeline Analysis
5.1 Overview
5.2 Vitaros (Alprostadil)
5.3 Uprima (Apomorphine)
5.4 Others (Topiglan, Melanocortin Activators, Gene Therapy)

6 Global Erectile Dysfunction Drugs Market, By Geography
6.1 Overview
6.2 North America
6.3 Europe
6.4 Asia-Pacific
6.5 Rest of the World (Row)

7 Competitive Landscape
7.1 Market Share Analysis: Global Erectile Dysfunction Drugs Market, 2012 (%)

8 Recommendations
8.1 Novel Drug Formulations and Genericization owing to Patent Expiration of well recognized ED Drugs
8.2 Mergers and Acquisitions to Strengthen Market Presence
8.3 Cost Containment Measures

9 Company Profiles

Companies Mentioned:

  • Apricus Biosciences, Inc
  • Bayer AG
  • Cristalia Produtos Quimicos Farmaceuticos Ltda
  • Dong-A Pharmaceutical Co Ltd
  • Eli Lilly And Company
  • Meda Pharmaceuticals, Inc
  • Pfizer, Inc
  • SK Chemicals Co Ltd
  • Vivus, Inc

For more information visit http://www.researchandmarkets.com/research/3zf33c/erectile

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
2. ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Attendees Save Up To $800 on Global Healthcare Conferences in 2012 by Registering Through Global Information Inc.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
8. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
11. Global Pharmaceutical Leaders All Converging in Parsippany, New Jersey on September 11-12, 2012 for Breakthrough Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017   Royal Philips (NYSE: ... in health technology, today announced 510(k) clearance from ... market its ElastQ Imaging capability, further expanding the ... ElastQ Imaging enables simultaneous imaging of tissue and ... the diagnosis of various liver conditions. With ElastQ ...
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
(Date:2/27/2017)... , Feb. 27, 2017  CTI BioPharma Corp. (CTI BioPharma) ... Adam Craig , M.D., Ph.D., as President and Chief Executive ... March 20, 2017. Dr. Craig succeeds Richard Love , ... the company,s Board of Directors.  Dr. Craig has over 20 ... both the US and Europe . ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based ... In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds 150,000. ... company had 800 customers and 2,250 RCEs at the time of acquisition. In ...
(Date:2/27/2017)... , ... February 27, 2017 , ... New Jersey ranks ... among all types and genders. And the need for advanced services is growing. ... its top-rated cancer care program, in collaboration with their non-profit partners in their fight ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... NuevaCare, a ... as diverse as Millbrae, Belmont, and Palo Alto, is proud to announce an important ... Bay Area consumers look for home care close to home, and by having city-specific ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ODH, Inc.™ ... Summit, February 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director ... to use behavioral health analytics to improve Medicaid population health management. , ODH will ...
(Date:2/24/2017)... Prior Lake MN (PRWEB) , ... February 24, ... ... the launch of its newly designed TaskMate Go. Core benefits and advantages built ... grain finish and a stylish, functional look and feel. Ability to gain the ...
Breaking Medicine News(10 mins):